CAS:899713-86-1ML348

您的位置 : 首页 / Metabolic Enzyme / Phospholipase / ML348

ML348 ML348 Cat No. FB10074Cas No. 899713-86-1

ML348 is a selective and reversible lysophospholipase 1 (LYPLA1) inhibitor (IC50 = 210 nM), Exhibits 14-fold selectivity for LYPLA1 over LYPLA2, Also selective over a panel of ~30 other serine hydrolases.

规格	价格	促销价格	库存

18817579266

立即询价

咨询

18817579266

立即询价

实验数据

储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 2.4050 mL
- 12.0252 mL
- 24.0504 mL
- 5 mM
- 0.4810 mL
- 2.4050 mL
- 4.8101 mL
- 10 mM
- 0.2405 mL
- 1.2025 mL
- 2.4050 mL
计算器摩尔计算器总药量计算器工作液计算器

技术信息

CAS号

899713-86-1

储存条件

粉末: -20°C 3 年

液体: -80°C 12 月

分子式

C18H17ClF3N3O3

运输

蓝冰

分子量

415.79

别名

溶解度

DMSO	40.0 mg/mL (96.2 mM)
Water	insoluble

动物实验配方

靶点数据

生物活性

描述Protein palmitoylation, an important post-translational modification necessary for trafficking and localization of regulatory proteins, plays key roles in cell growth and signaling. Palmitoylation is required for malignant transformation of multiple oncogenes, including HRAS and SRC. Lysophospholipase 1 (LYPLA1) has been confirmed as a palmitoyl thioesterase that is responsible for HRAS depalmitoylation in mammalian cells. ML348 is a selective and reversible LYPLA1 inhibitor with IC50 value of 210 nM and K_i value of 280 nM. ML348 showed no cytotoxic effects on human embryonic kidney cells (HEK293T). Maximum soluble drug concentrations of ML348 treatment (<12.5 μM) did not decrease cell viability, but led to a slight activation of AKT in NRAS mutant cells.
作用机制ML348 inhibits LYPLA1 by occupying a putative acyl-binding region, establishing the mechanism for isoform-specific inhibition and hydrolysis of acyl substrates.
动物研究
剂量
Mice: 50 mg/kg^[1] (i.p.)

给药途径
i.p.

动物研究
剂量	Mice: 50 mg/kg^[1] (i.p.)
给药途径	i.p.